{"id":"https://openalex.org/W4404100970","doi":"https://doi.org/10.1183/13993003.congress-2024.pa885","title":"The anti-IL-33 antibody, itepekimab, potently blocks airway inflammation post a single dose in mice","display_name":"The anti-IL-33 antibody, itepekimab, potently blocks airway inflammation post a single dose in mice","publication_year":2024,"publication_date":"2024-09-14","ids":{"openalex":"https://openalex.org/W4404100970","doi":"https://doi.org/10.1183/13993003.congress-2024.pa885"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2024.pa885","doi":"https://doi.org/10.1183/13993003.congress-2024.pa885","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2024.pa885","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018281721","display_name":"Seblewongel Asrat","orcid":"https://orcid.org/0000-0001-9953-7120","observed_orcids":["https://orcid.org/0000-0001-9953-7120"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seblewongel Asrat","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033599261","display_name":"Randi Foster","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randi Foster","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059053054","display_name":"George M. Scott","orcid":"https://orcid.org/0000-0001-8001-5779","observed_orcids":["https://orcid.org/0000-0001-8001-5779"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George Scott","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027502675","display_name":"Dylan Birchard","orcid":"https://orcid.org/0009-0007-6493-1030","observed_orcids":["https://orcid.org/0009-0007-6493-1030"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dylan Birchard","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111818752","display_name":"Li-Hong Ben","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li-Hong Ben","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022086818","display_name":"Jeanne Allinne","orcid":"https://orcid.org/0009-0008-5887-3820","observed_orcids":["https://orcid.org/0009-0008-5887-3820"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeanne Allinne","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Andrew Murphy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Murphy","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010366910","display_name":"Pamela Krueger","orcid":"https://orcid.org/0000-0002-6166-7189","observed_orcids":["https://orcid.org/0000-0002-6166-7189"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela Krueger","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109122967","display_name":"Matthew Sleeman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew Sleeman","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018894996","display_name":"Jamie Marie Orengo","orcid":"https://orcid.org/0000-0002-2695-6508","observed_orcids":["https://orcid.org/0000-0002-2695-6508"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jamie Orengo","raw_affiliation_strings":["1Regeneron Pharmaceutical, Tarrytown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Regeneron Pharmaceutical, Tarrytown, United States","institution_ids":["https://openalex.org/I186523950"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I186523950"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA885","last_page":"PA885"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12528","display_name":"IL-33, ST2, and ILC Pathways","score":0.7333999872207642,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12528","display_name":"IL-33, ST2, and ILC Pathways","score":0.7333999872207642,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.2587999999523163,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/house-dust-mites","display_name":"house dust mites","score":0.6299999952316284},{"id":"https://openalex.org/keywords/allergic-airway-inflammation","display_name":"allergic airway inflammation","score":0.8730000257492065},{"id":"https://openalex.org/keywords/type-2-inflammation","display_name":"type 2 inflammation","score":0.8899999856948853},{"id":"https://openalex.org/keywords/lung-eosinophilia","display_name":"lung eosinophilia","score":0.7630000114440918},{"id":"https://openalex.org/keywords/lung-remodeling","display_name":"lung remodeling","score":0.7089999914169312},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8389999866485596},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9940000176429749},{"id":"https://openalex.org/keywords/humanized-mouse-model","display_name":"humanized mice","score":0.5600000023841858},{"id":"https://openalex.org/keywords/asthma","display_name":"asthma","score":0.4320000112056732},{"id":"https://openalex.org/keywords/chronic-obstructive-pulmonary-disease","display_name":"chronic obstructive pulmonary disease","score":0.8980000019073486}],"concepts":[{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.6103561520576477},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5440636277198792},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.39366862177848816},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33280491828918457},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3238913416862488}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2024.pa885","doi":"https://doi.org/10.1183/13993003.congress-2024.pa885","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2024.pa885","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.5400000214576721}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4387497383","https://openalex.org/W2948807893","https://openalex.org/W2899084033","https://openalex.org/W2778153218","https://openalex.org/W2748952813","https://openalex.org/W1531601525","https://openalex.org/W4391375266","https://openalex.org/W3031052312","https://openalex.org/W4389568370","https://openalex.org/W3032375762"],"abstract_inverted_index":{"Introduction:":[0],"Blockade":[1],"of":[2,33,69,86,94,105,150,176,184,195,217,228],"IL-33":[3,131,218],"using":[4],"itepekimab,":[5],"a":[6,36,120,165,180,214,240],"high":[7],"affinity":[8],"fully":[9],"human":[10],"IgG4":[11,170],"monoclonal":[12],"antibody,":[13],"has":[14],"shown":[15],"benefit":[16],"in":[17,35,61,108,128,148,173,193,202,226,239],"early":[18],"asthma":[19],"and":[20,29,67,73,84,90,111,198,230],"COPD":[21],"clinical":[22],"studies.":[23],"Here,":[24],"we":[25],"performed":[26],"pharmacokinetic":[27],"(PK)":[28],"pharmacodynamic":[30],"(PD)":[31],"assessment":[32],"itepekimab":[34,95,118,145,185,212],"house":[37],"dust":[38],"mite":[39],"(HDM)-driven":[40],"lung":[41,65,82,110,187,237,243],"inflammation":[42,60,79,188,233,244],"mouse":[43,245],"model.":[44,246],"Results:":[45],"Itepekimab":[46],"doses":[47,220],"ranging":[48],"from":[49],"25mg/kg":[50],"down":[51],"to":[52,98,114,124],"1mg/kg":[53,93,182],"potently":[54],"blocked":[55],"type":[56,74],"2":[57,189],"(T2)":[58],"airway":[59,78,101,232],"mice,":[62,133],"measured":[63,80],"by":[64,81],"eosinophilia":[66],"production":[68,85],"IL-4,":[70],"IL-5,":[71],"IL-13,":[72],"1/type":[75],"17":[76],"(T1/17)":[77],"neutrophilia,":[83],"MPO,":[87],"IL-1b,":[88],"TNF-a":[89],"MCP-1.":[91],"Consistently,":[92],"was":[96,146],"sufficient":[97],"improve":[99],"consolidation,":[100],"mucus":[102],"plugging,":[103],"expression":[104,197],"pro-fibrotic":[106],"genes":[107],"the":[109,174,203],"prevented":[112],"progression":[113],"severe":[115],"disease.":[116],"Interestingly,":[117],"exhibited":[119],"similar":[121],"PK":[122],"profile":[123],"an":[125,169],"isotype":[126],"control":[127],"HDM":[129,151,178],"challenged":[130,152],"humanized":[132],"suggesting":[134,164],"low":[135,222],"target":[136],"mediated":[137],"clearance":[138],"for":[139,154],"itepkimab.":[140],"When":[141],"dosed":[142],"at":[143,219],"1mg/kg,":[144,224],"detectable":[147],"circulation":[149],"mice":[153],"more":[155],"than":[156],"60":[157],"days":[158],"(>2":[159],"months)":[160],"post":[161],"mAb":[162],"exposure,":[163,179],"half-life":[166],"consistent":[167],"with":[168],"antibody.":[171],"Notably,":[172],"context":[175],"ongoing":[177],"single":[181],"dose":[183],"subdued":[186],"months":[190],"post-treatment,":[191],"resulting":[192,225],"reduction":[194,227],"cytokine/chemokine":[196],"immune":[199],"cell":[200],"activation":[201],"airway.":[204],"Conclusion:":[205],"Taken":[206],"together,":[207],"these":[208],"results":[209],"highlight":[210],"that":[211],"is":[213],"potent":[215],"blocker":[216],"as":[221,223,234,236],"T1/T17":[229],"T2":[231],"well":[235],"remodeling":[238],"chronic":[241],"progressive":[242]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}